Tumour Models, London

London 2 - 4 December 2013
 

 Tumour Models, London

Improved preclinical models. Clinically relevant predictions. Confidence in candidate progression. A transformed oncology pipeline.


Building modeling on the success of the inaugural Tumour Models London, the 2nd Annual meeting will revolutionise your approach to preclinical tumour.

With an even greater focus on the challenges large and small drug developers are currently struggling to overcome, the 2nd Annual Tumour Models Londonwill give you the knowledge and tools you need to develop and utilise the very best preclinical oncology models, and bring successful cancer drugs into the clinic.

Bringing together a perfect cocktail of expert speakers from big and small pharma/biotech, in just 3 days this meeting will help you to:

Make clinically relevant predictions by developing tumour models that are truly representative of patient outcomes, with discussions led by keynote presenter Norman Greenberg

Improve translational success through early identification of clinically relevant biomarkers with Janssen

Minmise late stage attrition and demonstrate a striking correlation between your preclinical data packages and observations in the clinic with Teva Pharmaceuticals and Orion Pharma

Devise effective preclinical strategies to improve the development of immuno-oncology agents by selecting immunologically relevant in vivo models with EMD Serono

Progress candidates down the pipeline by ensuring effective, accurate analysis and interpretation of the data from your models with AstraZeneca


Autore: Staff
Fonte: Sito web Tumour models